Loading...
XSHG
603676
Market cap588mUSD
Oct 09, Last price  
9.18CNY
1D
1.44%
1Q
4.79%
IPO
4.79%
Name

Tibet Weixinkang Medicine Co Ltd

Chart & performance

D1W1MN
XSHG:603676 chart
P/E
17.16
P/S
3.52
EPS
0.54
Div yield, %
3.61%
Shrs. gr., 5y
0.66%
Rev. gr., 5y
9.68%
Revenues
1.14b
-12.65%
342,297,569390,794,633440,233,687426,360,894420,381,506746,324,814740,963,154715,666,8061,033,622,5241,398,543,0261,322,649,2861,300,234,5191,135,750,213
Net income
233m
-5.41%
82,950,458106,735,940112,934,725114,915,842101,587,29173,435,93255,677,79058,424,81495,911,106176,958,348214,016,884246,169,206232,854,914
CFO
186m
-50.23%
88,588,900118,472,228114,468,946103,788,12563,300,67883,167,651106,340,781133,697,656170,688,769246,153,584256,672,272372,780,944185,531,542
Dividend
Jun 29, 20260.18 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tibet Weixinkang Medicine Co., Ltd., a pharmaceutical enterprise headquartered in Lhasa, China, is dedicated to the entire lifecycle of medicinal products within the country, encompassing their research and development, manufacturing, and sales. The company's diverse range of offerings includes specialized vitamins for parenteral nutrition, electrolyte solutions, intravenous iron preparations, antibiotic medications, and therapies designed for digestive system and liver conditions. Among its specific injectable products are multivitamins, potassium magnesium aspartate, iron sucrose, and potassium aspartate. Established in 2006, the firm operated under the name Weixinkang Medicine Youxian Gongsi until its rebranding to Tibet Weixinkang Medicine Co., Ltd. occurred in 2015.

Key people

Yong Zhang
Chairman of the Board, General Manager
Yanxia Zheng
Chief Financial Officer · since 2020
Weiqiang Liu
General Manager (rotating), Deputy General Manager · since 2025
Shigong Chen
Deputy General Manager, Director · since 2021
Feng Liu
Vice Chairman of the Board, Deputy General Manager · since 2023
Zizhong Weng
Deputy General Manager
Hong Zhang
Deputy General Manager · since 2025
Xiaobing Zhou
Deputy General Manager · since 2020
Haibo Yu
Secretary of the Board · since 2021
Binbin Liu
Director · since 2021
Lei Cao
Independent Director · since 2021
Xiaofang Xu
Independent Director · since 2021
Yanping Zhao
Independent Director · since 2021
IPO date
Jul 21, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT